サマリー

ブラジルのヒト型インスリン製剤市場 2022-2026 年
Technavioはブラジルのヒト型インスリン製剤市場を監視しており、2022年から2026年の間に1億3741万ドルの成長が見込まれ、予測期間中にCAGR5.44％で進行しています。当レポートでは、ブラジルのヒトインスリン製剤市場について、市場規模や予測、動向、成長促進要因、課題などの全体的な分析に加え、約25社のベンダーを網羅したベンダー分析も提供しています。
現在の市場シナリオ、最新動向とドライバー、市場全体の環境に関する最新の分析を提供しています。ブラジルの糖尿病有病率の上昇と人口動態の変化が市場を牽引しています。また、ブラジルにおける糖尿病の有病率の上昇は、市場の成長をも押し上げると予想されます。
ブラジルのヒト型インスリン製剤市場の分析には、製品、用途、流通経路の各セグメントが含まれます。
テクナビオのブラジルにおけるヒト用インスリン製剤市場のセグメント分けは以下の通りです。
製品別
- 基礎インスリンアナログ
- NPH
用途別
- I型糖尿病
- II型糖尿病
販売チャネル別
- 小売
- 病院
本調査では、戦略的提携が今後数年間におけるブラジルのヒトインスリン製剤市場の成長を促進する主要な要因の1つであると位置付けています。
Technavioは、複数のソースからのデータを調査、合成、要約し、主要パラメータの分析によって、市場の詳細な姿を提示します。ブラジルのヒトインスリン製剤市場に関する弊社のレポートは、以下の分野を対象としています。
- ヒト用インスリン製剤の市場規模
- ヒト用インスリン製剤の市場予測
- ヒトインスリン製剤市場の産業分析
Technavioの強力なベンダー分析は、顧客が市場での地位を向上できるように設計されており、これに沿って本レポートでは、Biocon Ltd、Boston Scientific Corp、Eli Lilly and Co、EUROFARMA LABORATORIOS SA、Gulf Pharmaceutical Industries、Merck and Co.など、ブラジルにおけるヒトインスリン薬市場の主要ベンダー数社の詳細分析を提供します。Inc.、Novartis AG、Novo Nordisk AS、Sanofi SA、Wockhardt Ltd.などです。また、ブラジルのヒトインスリン製剤市場の分析レポートには、今後の動向と市場成長に影響を与える課題に関する情報も含まれています。これは、企業が今後訪れるすべての成長機会を戦略的に活用するのに役立つものです。
本調査は、業界の主要参加者からのインプットを含め、一次情報と二次情報の客観的な組み合わせを使用して実施しました。本レポートには、主要ベンダーの分析に加え、包括的な市場およびベンダーランドスケープが含まれています。本レポートの詳細については、https://www.technavio.com/report/human-insulin-drugs-market-industry-in-brazil-analysis をご覧ください。
Technavioは、利益、価格、競争、プロモーションなどの主要パラメータの分析により、複数のソースからのデータを調査、合成、総括する方法で、市場の詳細なイメージを提示します。また、業界の主要な影響力を持つ人物を特定することで、市場の様々な側面を提示しています。提示されるデータは、包括的で信頼性が高く、一次および二次にわたる広範な調査の結果です。Technavioの市場調査レポートは、正確な市場成長を予測するために、完全な競争環境と、定性的および定量的調査を用いた詳細なベンダー選定方法および分析を提供します。

ページTOPに戻る

目次

• 1. Executive Summary
o 1.1 Market Overview
o Exhibit 01: Key Finding 1
o Exhibit 02: Key Finding 2
o Exhibit 03: Key Finding 5
o Exhibit 04: Key Finding 6
o Exhibit 05: Key Finding 7
o Exhibit 06: Key Finding 8
• 2. Market Landscape
o 2.1 Market ecosystem
o Exhibit 07: Parent market
o Exhibit 08: Market Characteristics
o 2.2 Value chain analysis
o Exhibit 09: Value chain analysis: Pharmaceuticals
o 2.2.1 Research and development (R&D) and drug discovery
o 2.2.2 Integration and product development
o 2.2.3 Manufacturing
o 2.2.4 Outbound logistics
o 2.2.5 Marketing and sales
o 2.2.6 Support services
o 2.2.7 Innovation
• 3. Market Sizing
o 3.1 Market definition
o Exhibit 10: Offerings of vendors included in the market definition
o 3.2 Market segment analysis
o Exhibit 11: Market segments
o 3.3 Market size 2021
o 3.4 Market outlook: Forecast for 2021 - 2026
o 3.4.1 Estimating growth rates for emerging and high-growth markets
o 3.4.2 Estimating growth rates for mature markets
o Exhibit 12: Brazil - Market size and forecast 2021 - 2026 ($ million)
o Exhibit 13: Brazil market: Year-over-year growth 2021 - 2026 (%)
• 4. Five Forces Analysis
o 4.1 Five Forces Summary
o Exhibit 14: Five forces analysis 2021 & 2026
o 4.2 Bargaining power of buyers
o Exhibit 15: Bargaining power of buyers
o 4.3 Bargaining power of suppliers
o Exhibit 16: Bargaining power of suppliers
o 4.4 Threat of new entrants
o Exhibit 17: Threat of new entrants
o 4.5 Threat of substitutes
o Exhibit 18: Threat of substitutes
o 4.6 Threat of rivalry
o Exhibit 19: Threat of rivalry
o 4.7 Market condition
o Exhibit 20: Market condition - Five forces 2021
• 5. Market Segmentation by Product
o 5.1 Market segments
o The segments covered in this chapter are:
o o Basal insulin analog
o o NPH
o Exhibit 21: Product - Market share 2021-2026 (%)
o 5.2 Comparison by Product
o Exhibit 22: Comparison by Product
o 5.3 Basal insulin analog - Market size and forecast 2021-2026
o Exhibit 23: Basal insulin analog - Market size and forecast 2021-2026 ($ million)
o Exhibit 24: Basal insulin analog - Year-over-year growth 2021-2026 (%)
o 5.4 NPH - Market size and forecast 2021-2026
o Exhibit 25: NPH - Market size and forecast 2021-2026 ($ million)
o Exhibit 26: NPH - Year-over-year growth 2021-2026 (%)
o 5.5 Market opportunity by Product
o Exhibit 27: Market opportunity by Product
• 6. Market Segmentation by Application
o 6.1 Market segments
o The segments covered in this chapter are:
o o Type I diabetes
o o Type II diabetes
o Exhibit 28: Application - Market share 2021-2026 (%)
o 6.2 Comparison by Application
o Exhibit 29: Comparison by Application
o 6.3 Type I diabetes - Market size and forecast 2021-2026
o Exhibit 30: Type I diabetes - Market size and forecast 2021-2026 ($ million)
o Exhibit 31: Type I diabetes - Year-over-year growth 2021-2026 (%)
o 6.4 Type II diabetes - Market size and forecast 2021-2026
o Exhibit 32: Type II diabetes - Market size and forecast 2021-2026 ($ million)
o Exhibit 33: Type II diabetes - Year-over-year growth 2021-2026 (%)
o 6.5 Market opportunity by Application
o Exhibit 34: Market opportunity by Application
• 7 Market Segmentation by Distribution channel
o 7.1 Market segments
o The segments covered in this chapter are:
o o Retail
o o Hospitals
o Exhibit 35: Distribution channel - Market share 2021-2026 (%)
o 7.2 Comparison by Distribution channel
o Exhibit 36: Comparison by Distribution channel
o 7.3 Retail - Market size and forecast 2021-2026
o Exhibit 37: Retail - Market size and forecast 2021-2026 ($ million)
o Exhibit 38: Retail - Year-over-year growth 2021-2026 (%)
o 7.4 Hospitals - Market size and forecast 2021-2026
o Exhibit 39: Hospitals - Market size and forecast 2021-2026 ($ million)
o Exhibit 40: Hospitals - Year-over-year growth 2021-2026 (%)
o 7.5 Market opportunity by Distribution channel
o Exhibit 41: Market opportunity by Distribution channel
• 8 Customer landscape
o 8.1 Overview
o Exhibit 42: Customer landscape
• 9. Drivers, Challenges, and Trends
o 9.1 Market drivers
o 9.1.1 Rising prevalence of diabetes in Brazil
o 9.1.2 Demographic transition in Brazil
o 9.1.3 Strategic alliances
o 9.2 Market challenges
o 9.2.1 High cost of human insulin drugs
o 9.2.2 Unknown etiology of type I diabetes
o 9.2.3 Unavailability of specific biomarkers
o Exhibit 43: Impact of drivers and challenges
o 9.3 Market trends
o 9.3.1 Advent of biosimilars
o 9.3.2 Increasing initiatives by vendors
o 9.3.3 Technological advancements
• 10. Vendor Landscape
o 10.1 Overview
o Exhibit 44: Vendor landscape
o 10.2 Landscape disruption
o Exhibit 45: Landscape disruption
o Exhibit 46: Industry risks
• 11. Vendor Analysis
o 11.1 Vendors covered
o Exhibit 47: Vendors covered
o 11.2 Market positioning of vendors
o Exhibit 48: Market positioning of vendors
o 11.3 Biocon Ltd.
o Exhibit 49: Biocon Ltd. - Overview
o Exhibit 50: Biocon Ltd. - Business segments
o Exhibit 51: Biocon Ltd. - Key News
o Exhibit 52: Biocon Ltd. - Key offerings
o Exhibit 53: Biocon Ltd. - Segment focus
o 11.4 Boston Scientific Corp.
o Exhibit 54: Boston Scientific Corp. - Overview
o Exhibit 55: Boston Scientific Corp. - Business segments
o Exhibit 56: Boston Scientific Corp. - Key offerings
o Exhibit 57: Boston Scientific Corp. - Segment focus
o 11.5 Eli Lilly and Co.
o Exhibit 58: Eli Lilly and Co. - Overview
o Exhibit 59: Eli Lilly and Co. - Business segments
o Exhibit 60: Eli Lilly and Co. - Key News
o Exhibit 61: Eli Lilly and Co. - Key offerings
o Exhibit 62: Eli Lilly and Co. - Segment focus
o 11.6 EUROFARMA LABORATORIOS SA
o Exhibit 63: EUROFARMA LABORATORIOS SA - Overview
o Exhibit 64: EUROFARMA LABORATORIOS SA - Product and service
o Exhibit 65: EUROFARMA LABORATORIOS SA - Key offerings
o 11.7 Gulf Pharmaceutical Industries
o Exhibit 66: Gulf Pharmaceutical Industries - Overview
o Exhibit 67: Gulf Pharmaceutical Industries - Product and service
o Exhibit 68: Gulf Pharmaceutical Industries - Key offerings
o 11.8 Merck and Co. Inc.
o Exhibit 69: Merck and Co. Inc. - Overview
o Exhibit 70: Merck and Co. Inc. - Business segments
o Exhibit 71: Merck and Co. Inc. - Key offerings
o Exhibit 72: Merck and Co. Inc. - Segment focus
o Exhibit 83: Mahaphant Fiber Cement Pvt. Ltd. - Key offerings
o 11.9 Novartis AG
o Exhibit 73: Novartis AG - Overview
o Exhibit 74: Novartis AG - Business segments
o Exhibit 75: Novartis AG - Key offerings
o Exhibit 76: Novartis AG - Segment focus
o 11.10 Novo Nordisk AS
o Exhibit 77: Novo Nordisk AS - Overview
o Exhibit 78: Novo Nordisk AS - Business segments
o Exhibit 79: Novo Nordisk AS - Key offerings
o Exhibit 80: Novo Nordisk AS - Segment focus
o 11.11 Sanofi SA
o Exhibit 81: Sanofi SA - Overview
o Exhibit 82: Sanofi SA - Business segments
o Exhibit 83: Sanofi SA - Key offerings
o Exhibit 84: Sanofi SA - Segment focus
o 11.12 Wockhardt Ltd.
o Exhibit 85: Wockhardt Ltd. - Overview
o Exhibit 86: Wockhardt Ltd. - Business segments
o Exhibit 87: Wockhardt Ltd. - Key offerings
o Exhibit 88: Wockhardt Ltd. - Segment focus
• 12. Appendix
o 12.1 Scope of the report
o 12.1.1 ????Market definition
o 12.1.2 Objective
o 12.1.3 Notes and caveats
o 12.2 Currency conversion rates for US$
o Exhibit 89: Currency conversion rates for US$
o 12.3 Research Methodology
o Exhibit 90: Research Methodology
o Exhibit 91: Validation techniques employed for market sizing
o Exhibit 92: Information sources
o 12.4 List of abbreviations
o Exhibit 93: List of abbreviations

•
• 1: Key Finding 1
• 2: Key Finding 2
• 3: Key Finding 5
• 4: Key Finding 6
• 5: Key Finding 7
• 6: Key Finding 8
• 7: Parent market
• 8: Market characteristics
• 9: Offerings of vendors included in the market definition
• 10: Market segments
• 11: Global - Market size and forecast 2021 - 2026 ($ million)
• 12: Global market: Year-over-year growth 2021 - 2026 (%)
• 13: Five forces analysis 2021 & 2026
• 14: Bargaining power of buyers
• 15: Bargaining power of suppliers
• 16: Threat of new entrants
• 17: Threat of substitutes
• 18: Threat of rivalry
• 19: Market condition - Five forces 2021
• 20: Product - Market share 2021-2026 (%)
• 21: Comparison by Product
• 22: Basal insulin analog - Market size and forecast 2021-2026 ($ million)
• 23: Basal insulin analog - Year-over-year growth 2021-2026 (%)
• 24: NPH - Market size and forecast 2021-2026 ($ million)
• 25: NPH - Year-over-year growth 2021-2026 (%)
• 26: Market opportunity by Product
• 27: Application - Market share 2021-2026 (%)
• 28: Comparison by Application
• 29: Type I diabetes - Market size and forecast 2021-2026 ($ million)
• 30: Type I diabetes - Year-over-year growth 2021-2026 (%)
• 31: Type II diabetes - Market size and forecast 2021-2026 ($ million)
• 32: Type II diabetes - Year-over-year growth 2021-2026 (%)
• 33: Market opportunity by Application
• 34: Distribution channel - Market share 2021-2026 (%)
• 35: Comparison by Distribution channel
• 36: Retail - Market size and forecast 2021-2026 ($ million)
• 37: Retail - Year-over-year growth 2021-2026 (%)
• 38: Hospitals - Market size and forecast 2021-2026 ($ million)
• 39: Hospitals - Year-over-year growth 2021-2026 (%)
• 40: Market opportunity by Distribution channel
• 41: Customer landscape
• 42: Impact of drivers and challenges
• 43: Vendor landscape
• 44: Landscape disruption
• 45: Industry risks
• 46: Vendors covered
• 47: Market positioning of vendors
• 48: Biocon Ltd. - Overview
• 49: Biocon Ltd. - Business segments
• 50: Biocon Ltd. - Key offerings
• 51: Biocon Ltd. - Key customers
• 52: Biocon Ltd. - Segment focus
• 53: Boston Scientific Corp. - Overview
• 54: Boston Scientific Corp. - Business segments
• 55: Boston Scientific Corp. - Key offerings
• 56: Boston Scientific Corp. - Key customers
• 57: Boston Scientific Corp. - Segment focus
• 58: Eli Lilly and Co. - Overview
• 59: Eli Lilly and Co. - Business segments
• 60: Eli Lilly and Co. - Key offerings
• 61: Eli Lilly and Co. - Key customers
• 62: Eli Lilly and Co. - Segment focus
• 63: EUROFARMA LABORATORIOS SA - Overview
• 64: EUROFARMA LABORATORIOS SA - Product and service
• 65: EUROFARMA LABORATORIOS SA - Key offerings
• 66: EUROFARMA LABORATORIOS SA - Key customers
• 67: EUROFARMA LABORATORIOS SA - Segment focus
• 68: Gulf Pharmaceutical Industries - Overview
• 69: Gulf Pharmaceutical Industries - Product and service
• 70: Gulf Pharmaceutical Industries - Key offerings
• 71: Gulf Pharmaceutical Industries - Key customers
• 72: Gulf Pharmaceutical Industries - Segment focus
• 73: Merck and Co. Inc. - Overview
• 74: Merck and Co. Inc. - Business segments
• 75: Merck and Co. Inc. - Key offerings
• 76: Merck and Co. Inc. - Key customers
• 77: Merck and Co. Inc. - Segment focus
• 78: Novartis AG - Overview
• 79: Novartis AG - Business segments
• 80: Novartis AG - Key offerings
• 81: Novartis AG - Key customers
• 82: Novartis AG - Segment focus
• 83: Novo Nordisk AS - Overview
• 84: Novo Nordisk AS - Business segments
• 85: Novo Nordisk AS - Key offerings
• 86: Novo Nordisk AS - Key customers
• 87: Novo Nordisk AS - Segment focus
• 88: Sanofi SA - Overview
• 89: Sanofi SA - Business segments
• 90: Sanofi SA - Key offerings
• 91: Sanofi SA - Key customers
• 92: Sanofi SA - Segment focus
• 93: Wockhardt Ltd. - Overview
• 94: Wockhardt Ltd. - Business segments
• 95: Wockhardt Ltd. - Key offerings
• 96: Wockhardt Ltd. - Key customers
• 97: Wockhardt Ltd. - Segment focus
• 98: Currency conversion rates for US$
• 99: Research Methodology
• 100: Validation techniques employed for market sizing
• 101: Information sources
• 102: List of abbreviations